Scientists are using artificial intelligence (AI) to help predict which embryos will result in IVF success. In a new study, AI was found to be more accurate than embryologists at pinpointing which embryos had the potential to result in the birth of a healthy baby. Experts from Sao Paulo State University in Brazil teamed up with Boston Place Clinic in London to develop the technology in collaboration with Dr Cristina Hickman, scientific adviser to the British Fertility Society. They believe the inexpensive technique has the potential to transform care for patients and help women achieve pregnancy sooner. During the process, AI was "trained" in what a good embryo looks like from a series of images. AI is able to recognise and quantify 24 image characteristics of embryos that are invisible to the human eye. These include the size of the embryo, texture of the image and biological characteristics such as the number and homogeneity of cells. During the study, which used cattle embryos, 48 images were evaluated three times each by embryologists and by the AI system. The embryologists could not agree on their findings across the three images, but AI led to complete agreement. Stuart Lavery, director of the Boston Place Clinic, said the technology would not replace examining chromosomes in detail, which is thought to be a key factor in determining which embryos are "normal" or "abnormal". He said: "Looking at chromosomes does work, but it is expensive and it is invasive to the embryo. What we are looking for here is something that can be universal. Instead of a human looking at thousands of images, actually a piece of software looks at them and is capable of learning all the time. As we get data about which embryos produce a baby, that data will be fed back into the computer and the computer will learn. "What we have found is that the technique is much more consistent than an embryologist, it is more reliable. It can also look for things that the human eye can't see." He said work was under way to look back at images from parents who had genetic screening and became pregnant. Applying AI to those images will help the computer learn, he said. Mr Lavery added: "This is an innovative and exciting project combining state of the art embryology with new advances in computer modelling, all with the aim of selecting the best possible embryo for transfer to give all our patients the best possible chance of having a baby. Although further work is needed to optimise the technique, we hope that a system will be available shortly for use in a clinical setting."

Read the original:
Artificial intelligence better than scientists at choosing successful IVF embryos - Independent Online

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today a new analysis of Rekovelle (follitropin delta) data that showed cumulative live birth rates were similar between women receiving Rekovelle and conventional follitropin alfa treatment.1 In addition, Rekovelle data from a separate new analysis showed a favourable safety profile in women with high anti-Mllerian hormone (AMH) levels.2 These analyses of the ESTHER-1 and ESTHER-2 Phase III clinical trials3,4 were presented today at the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Geneva, Switzerland.

Rekovelles individualised dosing regimen, based on a patients AMH level and body weight, provides clinicians with a consistent, evidence-based approach to personalising treatment for their patients, said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals. These new Rekovelle analyses add further evidence for a personalised approach to fertility treatment for patients.

A new analysis of the ESTHER-1 and ESTHER-2 trials showed that in women undergoing in vitro fertilisation (IVF), the cumulative live birth rate for fresh embryo transfers after three treatment cycles was 43.9% (292/665) with Rekovelle and 44.5% (294/661) with follitropin alfa.1 In addition, ongoing pregnancy rate was 45.1% (300/665) and 45.7% (302/661), respectively.1 The ESTHER trials3,4 were not powered for this analysis, so no confirmatory conclusions can be derived.

A separate new analysis of the ESTHER-1 trial was conducted to evaluate ongoing pregnancy rates, early ovarian hyperstimulation syndrome (OHSS) and preventive interventions for early OHSS in women with different AMH levels.2 For women with high AMH 35 pmol/L (13% of the trial population) the incidence of early OHSS with Rekovelle was lower (4.7%, 4/86) compared with conventional follitropin alfa dosing (11.9%, 10/84). The number of patients requiring preventive interventions for early OHSS was also lower (4.7%, 4/86 and 23.8%, 20/84 respectively). In addition, patients maintained ongoing pregnancy rate.2 The ESTHER trials3,4 were not powered for this analysis, so no confirmatory conclusions can be derived.

- ENDS -

About Rekovelle(follitropin delta) Rekovelle is the first recombinant follicle stimulating hormone (rFSH) derived from a human cell line (PER.C6 cell line).3,5,6,7 It has been developed for individualised dosing based on a patients body weight and serum AMH level, as determined by a companion diagnostic, the Elecsys AMH Plus immunoassay from Roche.3,8,9 Rekovelle is structurally and biochemically distinct from other existing recombinant FSH treatments.3,5,6,7

Rekovelle received Marketing Authorisation from the European Commission (EC) in December 2016.

About the ESTHER trials ESTHER-1 (Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World) is a Phase 3, randomised, assessor-blind, controlled trial of 1326 patients in 11 countries undergoing their first ART cycle. Patients were randomized 1:1 to receive treatment with individualised Rekovelle, a fixed daily dose based on serum anti-Mllerian hormone (AMH) levels and body weight, or conventional follitropin alfa dosing. The co-primary endpoints of ongoing pregnancy rates and ongoing implantation rates were met and results showed no difference between the two treatment arms. Results of the ESTHER-1 trial were published in the February 2017 issue of Fertility & Sterility.3

ESTHER-2 is a Phase 3, assessor-blind, controlled trial evaluating the immunogenicity of Rekovelle in a subset of ESTHER-1 patients undergoing repeated cycles of controlled ovarian stimulation for ART. Data demonstrated no increased immunogenicity risk with Rekovelle after exposure in repeated cycles.4

About AMH and OHSS AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.10 Women with high AMH levels are at an increased risk of developing OHSS, a potential complication of IVF treatment.11,12 Symptoms of early OHSS may include abdominal distension or discomfort, nausea and vomiting. In more severe cases OHSS can lead to large amounts of ascites (fluid accumulation in the abdominal cavity), shortness of breath, blood clots, dehydration and potentially, death.11

The prevalence of OHSS in women undergoing IVF varies according to severity, with cases of OHSS experienced by 2033% (mild), 36% (moderate) and 0.12% (severe) of women.13 A recent report suggested that OHSS is an underreported side effect of ovarian stimulation and the real world incidence may be higher.14 In addition to the impact on patients, the treatment of OHSS is associated with significant costs to the healthcare system.15 In the UK for example, the cost of treating moderate and severe cases of OHSS is estimated to be over 7 million every year.15,16

About Ferring Pharmaceuticals Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the companys research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit http://www.ferring.com.

About the ElecsysAMH Plus immunoassay from Roche The Elecsys AMH Plus immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels.8,9,17,18,19,20 This fully automated Elecsys AMH Plus immunoassay, run on the cobase and Elecsys immunoassay analysers, determines AMH levels in 18 minutes, making it appropriate for routine clinical use. The Elecsys AMH Plus immunoassay is intended to be used for assessment of ovarian reserve, prediction of response to COS and establishment of the individual daily dose of Rekovelle in combination with body weight in COS for the development of multiple follicles in women undergoing an assisted reproductive technology programme.8,9,17,18,19,20

References

1 Havelock J, Bosch E, Sanchez F, et al. Cumulative ongoing pregnancy and live birth rates following repeated controlled ovarian stimulation (COS) cycles using individualised follitropin delta dosing compared to conventional follitropin alfa dosing [abstract] In: 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2017; Geneva, Switzerland. Abstract no. 0-168

2 La Marca A, Nelson S, Gothberg M, et al. The impact of serum anti-Mllerian hormone (AMH) levels on clinical outcome of individualized follitropin delta dosing and conventional follitropin alfa dosing in controlled ovarian stimulation [abstract]. In: 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2017; Geneva, Switzerland. Abstract no. 0-174

3 Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualised versus conventional ovarian stimulation for an in vitro fertilization: a multicenter, randomized, controlled assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017: 107(2): 387-396

4 Buur Rasmussen A et al. Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: Results from phase 3 trials (ESTHER-1 and ESTHER-2). Human Reproduction 2016; 31: 385

5 Rekovelle Summary of Product Characteristics (SmPC) Available at: https://www.medicines.org.uk/emc/medicine/33324 [Last accessed: June 2017]

6 Arce JC, Andersen AN, Fernndez-Snchez M, et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormonestratified, doseresponse trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014;102(6):16331640

7 Olsson H, Sandstrm R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014; 54(11):12991307

8 Deeks ED. Elecsys AMH assay: a review in anti-Mllerian hormone quantification and assessment of ovarian reserve. Mol Diagn Ther. 2015; 19: 245-249

9 Roche Diagnostics. Elecsys AMH (anti-Mullerian hormone): Method sheet. 2015. https://pim-eservices.roche.com. [Last accessed June 2017]

10 La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16(2):113-130

11 OHSS Symptoms and Causes. Patient Care and Health Information. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/ovarian-hyperstimulation-syndrome-ohss/symptoms-causes/dxc-20263586 [Last accessed: June 2017]

12 Salmassi A, Mettler L, et al. Cut-Off Levels of Anti-Mullerian Hormone for the Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome. Int J Fertil Steril. 2015; 9(2): 157-167

13 Delvigne A, Rozenberg S, et al. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; 8(6): 559-577

14 Thomsen L, Humaidan P, et al. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin. Curr Opin Obstet Gynecol. 2015; 27(3): 210-214

15 Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011; 26(9): 2353-2362

16 Fertility Treatment in 2014 Trends and Figures Report. Human Fertilisation and Embryology Authority. http://www.hfea.gov.uk/docs/HFEA_Fertility_treatment_Trends_and_figures_2014.pdf [Last accessed June 2017]

17 Gassner D, Jung R. First fully automated immunoassay for anti-Mllerian hormone. Clin Chem Lab Med. 2014;52(8):1143-1152

18 Anderson RA, Anckaert E, Bosch E, et al. Prospective study into the value of the automated Elecsys antimllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril. 2015;103(4):107480.e4

19 Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent antimllerian hormone assays. Fertil Steril. 2015;104(4):1016-1021.e6

20 Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-mullerian hormone in a clinical series. Reprod Biol Endocrinol. 2015;13(1):107

See more here:
Ferring Announces New Analysis of Rekovelle Data Relating to ... - Business Wire (press release)

The study of almost 19 000 IFV treatment cycles showed a decline in the success rate with increasing male partner age.

"Our study found an independent effect of male age on the cumulative incidence of live birth," said investigator Laura Dodge from Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, US.

The study, scheduled to be presented at the European Society of Human Reproduction and Embryology meeting in Geneva on Tuesday, was an analysis of all IVF cycles performed at a large IVF centre in the Boston region between 2000 and 2014, a total of almost 19 000 cycles performed in 7753 couples.

The female partners in these cycles were stratified according to four age bands - under 30, 30-35 years, 35-40 years and 40-42.

Men were stratified into these same four age bands, with an additional band of 42 and over.

As expected, the cumulative live birth rate (measured from up to six cycles of treatment) was lowest in those couples where the female partner was in the 40-42 age band, and in this group the age of the male partner had no impact, demonstrating the dominant detrimental effect of female age.

However, within the other bands of female age, the cumulative incidence of live birth was significantly affected by male partner age and was found to decline as the man grew older.

For example, in couples with a female partner aged under 30, a male partner aged 40-42 was associated with a significantly lower cumulative birth rate (46 percent) than a male partner aged 30-35 (73 percent).

Similarly, in couples with a female partner aged 35-40 years live birth rates were higher with a younger than with an older male partner.

"Women aged 35-40 did significantly benefit from having a male partner who is under age 30, in that they see a nearly 30% relative improvement in cumulative incidence of live birth when compared to women whose partner is 30-35 - from 54 percent to 70 percent," Dodge said.

For women between ages 30 and 35, having a partner who is older than they are is associated with approximately 11 percent relative decreases in cumulative incidence of live birth when compared with having a male partner within their same age band, Dodge said.

In natural conceptions increasing male age is associated with a decreased incidence of pregnancy, increased time to pregnancy, and increased risk of miscarriage, Dodge noted.

The mechanisms, she added, are unclear but may include impaired semen parameters, increased DNA damage in sperm, and epigenetic alterations in sperm that affect fertilisation, implantation, or embryo development.

-IANS

See the original post:
Male partner's age can affect IVF delivery success: Study - Independent Online

4th Jul 17 | Fitness & Wellbeing

Infants who begin life in a lab will end up heavier than peers who were conceived naturally, experts claim.

Babies born through in vitro fertilisation (IVF) treatment are more likely to be overweight, new research has discovered.

Experts from Maastricht University in the Netherlands claim that 'test tube' infants' genes are altered through the process and they weigh on average 1.5 pounds (700grams) more than babies conceived naturally by nine years old.

It's thought youngsters hold onto fat when not starting out in their mother's tummy, leading them to become heavier as time goes on.

To come to their conclusions, the researchers looked at 136 children born through IVF in the Netherlands. Focusing on youths aged nine-and-a-half and of average height, it was found that they came in at 1.5 pounds heavier than those of the same age and stature who didn't begin life in a laboratory.

The hormones in which women take in order to harvest their eggs could be the reason why the cells in the embryo change, causing the babies to store more fat.

"This is enough of a weight difference to be concerning, because overweight children are more likely to become overweight adults. We think IVF children may be predisposed to cardiovascular problems, including heart problems, in later life. They may be programmed wrongly by IVF to store food as fat throughout their lives," lead researcher Dr. Heleen Zandstra said.

Referring to the chemicals used during IVF, Dr. Zandstra noted it may mean infants are born smaller, but the weight issues will emerge later down the line.

"(The chemicals) might change the way the baby absorbs nutrients, or how the placenta passes them on," she added. "At an older age, this may cause a child born smaller to store more food as fat, because their body wants to make sure they get enough."

The study was presented at the European Society of Human Reproduction and Embryology conference in Geneva.

Cover Media Group 2017

Originally posted here:
IVF babies more likely to become overweight - TV3 Xpos - TV3.ie

A recent study reveals that women aren't the only ones who have to worry about a ticking biological clock

Women deal with the stigma of infertility issues in most societies. Manywomen of a certain age know the feeling of being told that their biological clock is ticking by well meaning relatives. However, a new study shows that a mans age also has a role to play in fertility. A recent Harvard Universitystudy, which is being presented atthe third annual meeting of theEuropean Society of Human Reproduction and Embryology in Geneva, Switzerland, shows that male fertility declines with age.

Our study found an independent effect of male age on the cumulative incidence of live birth, said investigator Dr Laura Dodge from the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, USA.

Researchers looked at 19 000 cycles in 7 753 couples over a four-year period in Boston.

In couples with a female partner aged under 30, a male partner aged 40-42 was associated with a significantly lower cumulative birth rate (46%) than a male partner aged 30-35 (73%). Similarly, in couples with a female partner aged 35-40 years, live birth rates were higher with a younger partner than with an older male partner, the researchers found.

Oneof the reasons for decreased fertility as men get older is genetic damage to the sperm.

Globally infertility is a significantproblem. A 2015 report, titledA unique view on male infertility around the globe,found that48,5 million couples around the world experience infertility and men contribute to an estimated 20%-30% of issues.

The burden of fertility often falls on women because of dominant patriarchal norms.

In an interview with DESTINY, Rhandzu Tshivhasi (34), who has been married to her husband for 10 years, said when people speculate on why the couple have not yet conceived, she finds it easier to be the one to admit she is infertile.

When a man is infertile, he is looked down upon. You find that other men actually laugh at him like its his fault, but its not, she said.

The Harvard study found that in some cases, women couldbenefit from having younger partners.

For women aged 30-35, having a older partner is associated with approximately 11% relative decreases in cumulative incidence of live birth from 70% to 64% when compared to having a male partner within the same age band, the researchers found.

Go here to read the rest:
Age has an effect on male fertility - study | DESTINY Magazine - DestinyConnect

A proton beam irradiating a brain tumour (circled in white) many anti-cancer therapies destroy fertility either chemically or through radiation. Photograph: Alamy Stock Photo

Women who survived cancer in the past 30 years were a third less likely to become pregnant than women in the general population, according to study into the impact of the disease and its treatment on patients.

The research provides the first broad assessment of how cancer, the fertility-harming therapies that patients receive, and the decisions women make on leaving hospital, can affect their plans for a family.

This really allows us to quantify the effects of cancer and its treatment, in the broadest sense, on women and girls having a pregnancy afterwards, said Richard Anderson, professor of clinical reproductive science, who led the work at Edinburgh University.

The scientists analysed medical records for more than 23,000 women in Scotland who survived cancer after being diagnosed between 1981 and 2012. The cancer survivors had only 6,627 pregnancies, far fewer than the 11,000 or so expected for an age-matched group of women in the general population.

A 30-year-old who has chemotherapy will have the reproductive potential of a 40-year-old

The impact of the disease was most striking for women who had not carried a baby before their diagnosis. The records showed that these women were about half as likely to conceive as similar but healthy women, with pregnancy rates of 21% versus 39%.

Many anti-cancer therapies are known to destroy fertility either chemically or through radiation, but many other factors will affect whether or not cancer survivors go on to have children. As well as the treatment damaging their fertility, its also women choosing not to complete their family, said Anderson. Some women may not want to bring another child into the world when they are not sure about their own health.

While the findings highlight the serious impact that cancer can have on female fertility and the choices women make around having children, the records point to a stark improvement in recent years, with some types of cancer now taking far less of a toll. In the 1980s, women who survived cancer were half as likely to conceive as others, but since 2005 pregnancy rates have risen to 75% of that seen in the healthy population.

Speaking from the European Society of Human Reproduction and Embryology in Geneva, Anderson said that doctors had seen clear improvements in pregnancy rates among survivors of some cancers but not others. For example, girls diagnosed with Hodgkin lymphoma today have far less radiotherapy than 30 years ago, causing less damage to their fertility. Similar improvements have not been seen in other cancers such as leukaemia, however.

The work highlights the need for more widespread access to new procedures that aim to preserve the fertility of girls and women who face cancer therapy. One approach is to remove ovarian tissue from the patient and freeze it until the patient has the all-clear and the tissue can be re-implanted. Last year, Anderson announced the first British birth using frozen ovarian tissue, to a 33-year-old woman who had part of an ovary removed 11 years earlier. Anderson said the latest findings should help doctors to counsel women who are diagnosed with cancer and direct services, such as ovarian tissue preservation, to where it is needed most.

Gillian Lockwood at Midland Fertility Services said that chemotherapy could add a decade to a womans reproductive age, an issue that must be taken into account in patient counselling. A 30-year-old who has chemotherapy will have the reproductive potential of a 40-year-old, which is not good, she said. Its important for these young women to know that even though their life expectancy thanks to good, modern oncology treatment is near normal, their reproductive life expectancy may not be as good.

Nick Macklon, professor of obstetrics and gynaecology at Southampton University, said the results were positive for many cancer patients. The knowledge that they can have a good chance of having a baby will be very important to women, and the addition of fertility preservation over the past few years has really changed the scene for them. Not so long ago, having a cancer diagnosis was seen as the end of your chances of having a baby, he said.

Read more:
Cancer-surviving women a third less likely to become pregnant ... - The Guardian

GENEVA, July 3, 2017 /CNW/ -- The European Society of Human Reproduction and Embryology's Annual Meeting in Geneva has today heard that a world first Australian invention has modernised one of the key IVF processes by automating and standardising steps that are currently performed manually.

Genea Biomedx's Gavi automates key stages of vitrification - the process of freezing IVF patients' embryos for use in later cycles or whilst awaiting results from genetic screening.

In Australia, the leading technology is exclusive to Genea clinics meaning only Genea patients have access to Gavi and its vitrification outcomes.

Results presented today show clinical outcomes of day five embryos vitrified using the Gavi system are comparable to the traditional manual CRYOTOP system. Gavi also offers time savings through standardising what is traditionally a highly manual process which is subject to environment and human variation.

"In IVF labs across the world, vitrification is currently undertaken many times each day, requiring a high level of manual dexterity and leading to variations between embryologists and clinics in the way embryos are handled and the outcomes achieved," Genea Biomedx General Manager Dr Tammie Roy said.

She added, "we know that the more experience an embryologist has in the manual process the better the outcomes. By implementing Gavi and therefore standardising the vitrification process, every embryo in the lab is treated exactly the same way despite the embryologist's level of experience".

In the Genea clinics that were assessed for this study the Gavi system provided immediate high level survival rates thus demonstrating the potential to reduce the learning curve that is experienced by embryologists in the manual process.

Vitrification of embryos is an essential component of an effective assisted conception program. Genea Medical Director, Associate Professor Mark Bowman said, "at Genea, most patients are likely to have more than one viable embryo so preserving extra embryos for patients to complete their family or try again is imperative." He added, "it's all part of our commitment to getting women pregnant in the least number of stimulated cycles."

Full media release here: http://geneabiomedx.com/Content/Files/MEDIA-RELEASE_Genea-Biomedx-GAVI_ESHRE_FINAL_Genev.aspx

Media Contact at ESHRE

Sophie Hegarty M: +61447 111 190 E: sophie.hegarty@geneabiomedx.com

* The selection of this abstract for publication in the press programme does not imply endorsement by ESHRE of the products and/or services

SOURCE Genea

More here:
Australian invention modernises IVF - CNW - Canada NewsWire (press release)

Cryos International Sperm and Egg bank is now offering both medical and elective fertility preservation for women. What was once an experimental procedure is now seen as an insurance policy for the future, taking the pressure off women to have children right away while preserving their eggs for the future.

Orlando, Florida (PRWEB) July 02, 2017

Cryos International Sperm and Egg Bank located in Orlando, Florida announced today that it would be expanding its range of services to include Social (elective) Egg Freezing. This is a welcome addition to their existing services of medical fertility preservation for both men and women, as well as elective fertility preservation for men. The company, which prides itself on helping to create families is proud to now provide women with the opportunity to preserve their fertility on their own terms.

In recent years, elective and medical fertility preservation for women and men has gained popularity. However, few practices have the experience and capability to offer egg freezing as a service. At Cryos, we have both the experience and the capability, as well as an onsite surgery center and state-of-the-art embryology lab, located at our Orlando, Florida facilities.

As of July 5th, 2017, Cryos will begin taking appointments for initial consultations so prospective clients can meet with one of our Clinical Coordinators. During this meeting, the process of Egg Freezing will be discussed in-depth to ensure that you aware of what the next steps are. Following that, an appointment will be scheduled with Dr. Mark Trolice - One of Orlando's top fertility experts, as well as being double board certified REI and OB/GYN. Watch his video on the right to watch him discuss his opinions on elective egg freezing.

For questions regarding Cryos' social or medical egg freezing services, please call us at 407-203-1175 or e-mail usa(at)cryosinternational(dot)com.

________________________________________________

About Cryos International

Celebrating 30 years of experience and delivering to more than 80 countries, Cryos International is a trusted industry leader. As the world's largest sperm bank, and first free-standing, independent egg bank in the United States, Cryos aims to ensure a wide selection of high-quality, extensively screened donor sperm and eggs from all races, ethnicities and phenotypes. To Cryos, high quality and professional service has always ranked as the most important issue in our relations with clients.

Cryos continuously works hard on improving and expanding its services.

For more information about Cryos International, visit our website.

To Cryos it's personal.

---

Media Contact:

Corey Burke Cryos International Tissue Bank Director 407-203-1175 Ext: 5003 cb(at)cryosinternational(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/07/prweb14476567.htm

More here:
Cryos International USA To Begin Social Egg Freezing Services in ... - Benzinga

During summer vacation I wake up early and then can sleep late on a long hot day after chores. But I learned that when raising animals that just because Im sick, I cant take the day off. Just because Im sick doesnt mean the animals are sick. Another thing is that I like working with animals more than field work. I never judge the animals. There is a special bond between us. Ill be out there loving on them while cleaning and feeding them. But its not the life for some people.

"Being on a farm introduced me to 4-H the best thing, hands down. There are not a lot of farm kids at Western Reserve but 4-H introduced me to other farm kids at the fair. I made friends around the whole county. We see each at various 4-H events. We meet at 4-H Camp Conger every year, too. It has been a camp for nearly a hundred years. Elaine Conger asked the campers how many of their parents went to camp here and a lot of hands went up. She asked how many grandparents went to camp and fewer hands went up. When she asked how many great-grandparents went here the circle got a lot smaller but I could say yes to all. There were only three of us in that circle.

Linder said the club opened him up to attend the Ohio State Fair and competing in the health and safety speech contest. He said the fair is a year-round event.

"Also when choosing my animal to show, it doesn't start two weeks or two months before the county fair. It starts two weeks after the fair, when we begin to clean up our barn and get ready for new animals to come in.

"This year we had three animals we were going to show, but one didnt have the right hair quality so two will go to Huron County and the state fair. They are on a schedule every day. In October they weighed 650 to 700 pounds. Now eight months later they hit 1,050 to 1,200. They still need to gain three to four pounds every day and are weighed every two weeks. You can tell a lot about their general health by their weight if they are sick or need to be vaccinated or if they have worms.

"This year I also have two boer goats but only one will go to the fair. Also, of the three hogs, only two will go to show. Besides four hours or more a day taking care of the steers, more time goes into getting these other animals ready. If Dad needs help in the field, I can go out and do that, but he makes sure I have time for the animals. I learned it may not always be fun, but if that's what you love you'll do the work anyway. It's in your heart and mind.

"From the beginning Dad has helped me start my own herd and now I have 12 cows. The first one was bought from winnings at the fair and now some have calves."

From all this work Linder has a growing investment and he even gets taxed, he says. Due to his continuing experience raising these animals, through 4-H, chores, and extra shows, he is planning to study embryology and animal husbandry in college.

Read more:
Western Reserve student learns responsibility through farming and 4-H - Norwalk Reflector

When a human egg is fertilized, the result is never a newborn platypus. I didnt need four years of medical school, three years of pediatric residency, three years of neonatal fellowship, and close to two decades of medical practice to tell me that. In fact, high-school biology textbooks explain that all fertilized human eggs (zygotes), after approximately nine months, become newborn human babies unless something occurs to interrupt normal development.

This progression from fertilized egg to newborn is neither alternative science nor a rejection of long-standing medical knowledge. Yet in her paper Alternative Science and Human Reproduction, published this month in the New England Journal of Medicine, R. Alta Charo uses those labels to discredit anyone who acknowledges the biological truth about human development.

Charo attempts in her piece to discredit Donald Trumps pro-life executive-branch appointees. To this end, Charo, who is not a doctor, paints as ludicrous the claim that contraceptives can act as abortifacients by disrupting the natural process of pregnancy and ending a human life.

In reality, the progression of events from sexual intercourse to the creation of new human life is well established.

The process goes something like this: About six days after fertilization of the egg, and multiple cell divisions later, the zygote has become a cluster of cells (now called a morula). It has traversed the mothers fallopian tube and made its way into her uterus, where the process of implantation will then occur over the next four to five days. The various stages of development will continue to unfold until birth. Uterine implantation provides the ideal environmental mix for human development. If either a drug or a device disrupts implantation, the originating events that began approximately six days earlier are stopped, and the pregnancy is prevented from progressing.

So it follows that devices or medications that impede implantation effectively end or abort a pregnancy. This reality contradicts Charos argument that contraceptives abortifacient action is just a politically potent assertion by [Trump] appointees. The potency of the assertion derives from the fact that it is true. As Charo admits, one of the ways contraceptives work is to disrupt implantation.

The government and many physicians, however, define pregnancy as beginning only after implantation. As a physician myself, I prefer not to ignore the physical changes that occur between the moment fertilization occurs and implantation in the mothers womb. According to my embryology textbook, Before We Are Born: Essentials of Embryology and Birth Defects, the zygote represents the beginning of a human being.

From the moment of fertilization, the new human has unique DNA that serves as the cellular blueprint for the duration of his or her entire life. This medical fact does not depend on implantation: It depends entirely on the uniting of the parents DNA. Nor does this fact depend on an elected officials opinion or a lawyers or even a doctors opinion about when life begins.

Admittedly, zygotes dont look like humans. However, at the time of my grandmothers death, she didnt look much like her childhood pictures, and if we could have seen her as an embryo, she would have looked even less like the woman she developed into. But her DNA was intact at fertilization and remained intact throughout her life. My ability to recognize her at various stages of her life did not determine whether or not she was alive. The same is true for prenatal life and postnatal life.

There are multiple medical and legal papers arguing about when we should recognize life the moment we should acknowledge as the beginning of a life and what rights an individual does or does not have at different stages of life. Unfortunately, the arguments on these questions often reflect the ideological agenda of the arguer instead of the medical reality, which is that a unique life is created at fertilization. The distortion of this physiological truth, Charos article notwithstanding, is what makes human reproduction in our era the victim of alternative science.

READ MORE: Little-Known Facts about Roe v. Wade Planned Parenthoods Century of Brutality Planned Parenthoods Annual Report: Abortions Are Up, Prenatal Care Is Down

Robin Pierucci is a wife, a mother of three, and a practicing neonatologist. She is a member of Women Speak for Themselves.

Read the original post:
When Does Life Begin? Pro-Choice 'Science' Ignores the Facts. - National Review